Our Dry AMD model combines blue light and A2E treatment of iPSC-derived RPE cells. Screen small molecule librairies with high-throughput assays. Test and validate your active coumpound with dedicated in vitro bioassays.
In vitro model that recapitulates key features of dry AMD pathophysiology, with a screenable endpoint (Live/dead cells in 96wp).
Full phenotypic, molecular and functional characteristics of in situ RPE.
Use our iPSC-derived in vitro model assay to improve the relevance of your ophthalmology dry AMD R&D
Screenable endpoint Live/Dead in 96 wells plate
Age-related Macular Degeneration (AMD) is an ophthalmologic disease causing irreversible partial vision loss or for the worst cases blindness.
AMD is the first cause of vision loss after 50 years old, and prevalence is about 25 % for people older than 75. It is estimated that it will affect nearly 196 million people worldwide in 2020, including 69 million cases in Europe (Wong et al., 2014).
There are two kinds of this pathology : atrophic and exudative AMD, also called respectively dry and wet AMD.
There are treatments for the exudative form such as anti-VEGF antibodies (ranibizumab and bevacizumab). The atrophic form, which corresponds to more than 90% of cases, doesn't have any satisfactory therapeutic option exists to prevent vision loss (Schmier et al., 2006).